News
ESSA Pharma to Participate in Multiple Upcoming Investor Conferences
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2020
ESSA Pharma Completes Public Offering for Aggregate Gross Proceeds of US$48,990,000
ESSA Pharma Announces Proposed Public Offering of Common Shares
ESSA Pharma Announces Pricing of Public Offering of Common Shares
ESSA Pharma Announces First Patient Dosed in a Phase 1 Clinical Trial of EPI-7386 for Metastatic Castration-Resistant Prostrate Cancer
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at the 2020 American Association for Cancer Research Virtual Annual Meeting II
ESSA Pharma to Present at Jefferies Virtual Healthcare Conference
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 2020 Virtual American Urological Association (AUA) Annual Meeting
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2020